NYSEAMERICAN:STXS Stereotaxis (STXS) Stock Price, News & Analysis $1.88 -0.02 (-1.05%) Closing price 04:10 PM EasternExtended Trading$1.88 0.00 (-0.27%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Stereotaxis Stock (NYSEAMERICAN:STXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Stereotaxis alerts:Sign Up Key Stats Today's Range$1.86▼$1.9650-Day Range$1.78▼$2.2252-Week Range$1.74▼$3.59Volume334,687 shsAverage Volume406,369 shsMarket Capitalization$183.26 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview Stereotaxis, Inc. is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff. The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia. In addition to the Niobe platform, Stereotaxis has introduced the Vdrive Robotic™ system and the EPOCH® solution, which further automate catheter control and sheath deflection to streamline workflow in the electrophysiology lab. Stereotaxis also offers training, installation and technical support services to help facilities adopt and optimize use of its robotic navigation technology. Founded in 1997 and headquartered in St. Louis, Missouri, Stereotaxis has installed systems at leading hospitals and cardiac centers across North America, Europe, the Middle East and Asia-Pacific. The company maintains strategic collaborations with key electrophysiology mapping and imaging partners to advance integration and clinical data collection. Stereotaxis is led by President and Chief Executive Officer Jim Corriveau, whose team brings extensive experience in medical device innovation, regulatory affairs and global product commercialization.AI Generated. May Contain Errors. Read More Stereotaxis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreSTXS MarketRank™: Stereotaxis scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingStereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.Upside PotentialStereotaxis has a consensus price target of $4.00, representing about 112.8% upside from its current price of $1.88.Amount of Analyst CoverageStereotaxis has received no research coverage in the past 90 days.Read more about Stereotaxis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Stereotaxis are expected to grow in the coming year, from ($0.18) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stereotaxis is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stereotaxis is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStereotaxis has a P/B Ratio of 13.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stereotaxis' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.43% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 8.79.Change versus previous monthShort interest in Stereotaxis has recently increased by 8.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStereotaxis does not currently pay a dividend.Dividend GrowthStereotaxis does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Stereotaxis this week, compared to 1 article on an average week.Search Interest1 people have searched for STXS on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Stereotaxis insiders have not sold or bought any company stock.Percentage Held by Insiders16.03% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stereotaxis' insider trading history. Receive STXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STXS Stock News HeadlinesWhy Stereotaxis (STXS) Could Be One of the Best Robotics Stocks to Buy Under $30May 2, 2026 | finance.yahoo.comStereotaxis stock up on first US MAGIC procedures post approvalApril 24, 2026 | msn.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 11 at 1:00 AM | Paradigm Press (Ad)Stereotaxis Announces First MAGiC Procedures in the United StatesApril 22, 2026 | globenewswire.comStereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026April 21, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Stereotaxis (STXS)April 16, 2026 | theglobeandmail.comRoth MKM Reaffirms Their Buy Rating on Stereotaxis (STXS)April 16, 2026 | theglobeandmail.comStereotaxis to acquire Robocath for $20M upfrontApril 16, 2026 | seekingalpha.comSee More Headlines STXS Stock Analysis - Frequently Asked Questions How have STXS shares performed this year? Stereotaxis' stock was trading at $2.30 on January 1st, 2026. Since then, STXS stock has decreased by 18.3% and is now trading at $1.88. How were Stereotaxis' earnings last quarter? Stereotaxis Inc. (NYSEAMERICAN:STXS) announced its quarterly earnings results on Monday, March, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $8.64 million for the quarter, compared to analyst estimates of $9.24 million. Stereotaxis had a negative net margin of 66.85% and a negative trailing twelve-month return on equity of 291.99%. Read the conference call transcript. Who are Stereotaxis' major shareholders? Top institutional investors of Stereotaxis include Sequoia Financial Advisors LLC (0.39%), Bank of New York Mellon Corp (0.20%) and Cherry Creek Investment Advisors Inc. (0.04%). View institutional ownership trends. How do I buy shares of Stereotaxis? Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stereotaxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings3/09/2026Today5/11/2026Next Earnings (Estimated)5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 STXS's financial health is in the Red zone, according to TradeSmith. STXS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:STXS CIK1289340 Webwww.stereotaxis.com Phone(314) 678-6100Fax314-678-6159Employees130Year FoundedN/APrice Target and Rating Average Price Target for Stereotaxis$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+112.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.64 million Net Margins-66.85% Pretax Margin-66.85% Return on Equity-291.99% Return on Assets-38.07% Debt Debt-to-Equity RatioN/A Current Ratio1.51 Quick Ratio1.09 Sales & Book Value Annual Sales$32.38 million Price / Sales5.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book13.43Miscellaneous Outstanding Shares97,480,000Free Float81,852,000Market Cap$183.26 million OptionableNot Optionable Beta1.34 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSEAMERICAN:STXS) was last updated on 5/11/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stereotaxis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stereotaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
